Additional file 1 of Unbiased combination screening on repurposed drugs reveals synergistic potential of copanlisib and cerivastatin against chemoresistant high-grade serous ovarian cancer

Supplementary Material 1: Supplementary Table 1: Clinical characteristics of HGSOC patients providing ascites for PADC cultures. Supplementary Table 2: DSS of 593 compounds across OVCAR3, OVCAR4, and Kuramochi cell lines. Supplementary Table 3: Compounds included in the MuSIC screening library with corresponding single-drug Z-scores in OVCAR3 cells. Supplementary Table 4: List of Primary and secondary antibodies for WB. Supplementary Table 5: DSS of OC standard-of-care chemotherapy drugs across 5 HGSOC cell lines. Supplementary Table 6: DSS of 112 selected compounds across five HGSOC cell lines. Supplementary Table 7: Potent drug combinations identified at 0.5 µM across 4 HGSOC cell lines.

补充材料1：
补充表1：用于获取原代腹水细胞培养（PADC cultures）的高级别浆液性卵巢癌（High-Grade Serous Ovarian Cancer, HGSOC）患者临床特征。
补充表2：593种化合物在OVCAR3、OVCAR4及Kuramochi细胞系中的药物敏感性评分（Drug Sensitivity Score, DSS）。
补充表3：MuSIC筛选文库所包含的化合物，及其在OVCAR3细胞中的单药Z评分（Z-scores）。
补充表4：蛋白质印迹（Western Blot, WB）所用一抗与二抗清单。
补充表5：5种高级别浆液性卵巢癌（HGSOC）细胞系中，卵巢癌（Ovarian Cancer, OC）临床标准治疗化疗药物的DSS（药物敏感性评分）。
补充表6：5种高级别浆液性卵巢癌（HGSOC）细胞系中，112种筛选获得的化合物的DSS（药物敏感性评分）。
补充表7：在4种高级别浆液性卵巢癌（HGSOC）细胞系中，于0.5 μM浓度下筛选得到的强效药物联合方案。